Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217928 | 0.83 | NPC1 (0.50) | MAPTNPC1SMN1; SMN2RAB9AALOX15 | |
| SCHEMBL5211059 | 0.75 | NPC1 (0.49) | MAPTNPC1SMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL28033827 | 0.72 | HPGD (0.51) | MAPTNPC1SMN1; SMN2RAB9AALOX15 | |
| SCHEMBL182010 | 0.72 | CES2 (0.71) | NPC1SMN1; SMN2RAB9AALOX15MAPK1 | |
| SCHEMBL30100844 | 0.71 | MAPT (1.00) | MAPTNPC1SMN1; SMN2RAB9AALOX15 | |
| SCHEMBL29848069 | 0.70 | MAPT (1.00) | MAPTNPC1SMN1; SMN2RAB9AALOX15 | |
| SCHEMBL11124320 | 0.69 | GAA (0.66) | MAPTNPC1SMN1; SMN2RAB9AALOX15 | |
| SCHEMBL1838907 | 0.69 | — | — | |
| SCHEMBL1704958 | 0.69 | — | — | |
| SCHEMBL1093916 | 0.69 | NPC1 (0.49) | MAPTNPC1SMN1; SMN2RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | claimed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | claimed |
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | APP, OXA1L, BACE1 | MAPT 63/4885NPC1 2027/4885SMN1; SMN2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.